Classer les publications sur l'année

  • BiomĂ©trie et Analyses de bases de donnĂ©es

    Respiratory syncytial virus-related hospital stays in adults in France from 2012 to 2021: A national hospital database study.

    LOUBET P, FERNANDES J, DE POUVOURVILLE G, SOSNOWIEZ K, ELONG A, GUILMET C, OMICHESSAN H, BUREAU I, FAGNANI F, EMERY C, NOUR ABOU CHAKRA C.

    Journal of Clinical Virology ; 2024; 171

  • Pharmaco-EpidĂ©miologie

    Asthma burden according to treatment steps in the French population-based cohort CONSTANCES.

    ROCHE N, NADIF R, FABRY-VENDRAND C, PILLOT L, THABUT G, TEISSIER C, BOUEE S, GOLDBERG M, ZINS M.

    Respir Med ; 2023;206:107057

  • BiomĂ©trie et Analyses de bases de donnĂ©es

    Non‑tuberculous mycobacterial pulmonary diseases in France: an 8 years nationwide study

    VEZIRIS N, ANDREJAK C, BOUEE S, EMERY C, OBRADOVIC M, CHIRON R.

    BMC Infectious Diseases ; 2021;21(1):1165

  • Pharmaco-EpidĂ©miologie

    Mepolizumab in a population with severe osinophilic asthma and corticosteroid dependence: results from French early access programme

    TAILLE C, CHANEZ P, DEVOUASSOUX G, DIDIER A, PISON C, GARCIA G, CHARRIOT J, BOUEE S, GRUBER A, PRIBIL C, BOURDIN A, HUMBERT M.

    Eur Respir J ; 2020;55(6)

  • BiomĂ©trie et Analyses de bases de donnĂ©es

    The Burden of Severe Asthma in France: A Case-Control Study Using a Medical Claims Database

    BOURDIN A, FABRY-VENDRAND C, OSTINELLI J, AIT-YAHIA M, DARNAL E, BOUEE S, LAURENDEAU C, BUREAU I, GOURMELEN J, CHOUAID C.

    J Allergy Clin Immunol Pract ; 2019;7(5):1477-1487

  • Économie de la santĂ©

    Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results.

    HOOGENDOORN M, CORRO RAMOS I, BALDWIN M, LUCIANI L, FABRON C, DETOURNAY B, PMH RUTTEN-VAN MÖLKEN M.

    Int J Chron Obstruct Pulmon Dis ; 2019;14:447-456

  • BiomĂ©trie et Analyses de bases de donnĂ©es

    An attempt at modeling COPD epidemiological trends in France

    BURGEL PR, LAURENDEAU C, RAHERISON C, FUHRMAN C, ROCHE N.

    Respir Res ; 2018;19(1):130

  • Pharmaco-EpidĂ©miologie

    Etude de validation de l’Ă©chelle BDI/TDI dans la bronchopneumopathie chronique obstructive

    LAURENDEAU C, PRIBIL C, PEREZ T, ROCHE N, M-C SIMEONI, DETOURNAY B

    Rev Mal Respir ; 26:735-743

  • Pharmaco-EpidĂ©miologie

    Prévalence de la bronchopneumopathie chronique obstructive (BPCO) : estimation pour la France

    BENARD E, DETOURNAY B, NEUKIRCH F, PRIBIL C, EL HASNAOUI A

    La Lettre du Pneumologue ; 8(4):158-163

  • Pharmaco-EpidĂ©miologie

    The SCOPE Study : Healthcare consumption related to patients with Chronic Obstructive Pulmonary Disease in France

    DETOURNAY B, PRIBIL C, FOURNIER M, HOUSSET B, HUCHON G, HUAS D, GODARD P, VOINET C, CHANAL I, JOURDANNE C, DURAND-ZALESKI I, the SCOPE Group

    Value Health ; 7(2):168-174

  • Économie de la santĂ©

    Costs associated with community acquired pneumonia in France

    GRECE SABA, LUIZ FLAVIO ANDRADE, JACQUES GAILLAT,  PIERRE BONNIN, CHRISTIAN CHIDIAC,  HAJNAL-GABRIELA ILLES,  HENRI LAURICHESSE,  JONATHAN MESSIKA, JEAN-DAMIEN RICARD,  BRUNO DETOURNAY,  PATRICK PETITPRETZ, GERARD DE POUVOURVILLE

    Eur J Health Econom ; 2018;19(4):533-544

  • Économie de la santĂ©

    Prise en charge et coûts de la bronchopneumopathie chronique obstructive en France en 2011

    LAURENDEAU C, CHOUAID C, ROCHE N, TERRIOUX P, GOURMELEN J , DETOURNAY B

    Rev Mal Respir ; 2015;32:682-91

  • Économie de la santĂ©

    Le coĂ»t de l’asthme en France et les implications Ă©conomiques de son niveau de contĂŽle

    GADENNE S, PRIBIL C, CHOUAID C, VERGNENEGRE A, DETOURNAY B

    Rev Mal Respir ; 2011;28(4):419-426

  • Économie de la santĂ©

    The association between asthma control, health care costs, and quality of life in France and Spain

    DOZ M, CHOUAID C, COM-RUELLE L, CALVO E, BROSA M, ROBERT J, DECUYPERE L, PRIBIL C, HUERTA A, DETOURNAY B

    BMC Pulm Med ; 2013;22:13-15